---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218250"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-05-12T12:15:16+00:00"
generated_at: "2026-05-12T12:22:15.980728+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path

## Summary
- Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.
- Cash and investments $138.2M as of March 31, 2026, expected to fund operations into 2028.
- Reached broad FDA alignment on registration path for CRB-701 in 2L HNSCC and cervical cancer; registrational study start expected summer 2026.
- Updated CRB-701 data to be presented at ASCO 2026; CANYON-1 obesity study (n=240) fully enrolled, topline data summer 2026.

## SEC filing metadata
- accession: 0001193125-26-218250
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-05-12T12:15:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/0001193125-26-218250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/crbp-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218250
- JSON: https://secwatch.observer/filing/0001193125-26-218250.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218250.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported first quarter ended March 31, 2026 results: net income net loss of approximately $23.0 million, EPS net loss per basic and diluted share of $1.23.
  - Period: first quarter ended March 31, 2026
  - Net income: net loss of approximately $23.0 million
  - EPS: net loss per basic and diluted share of $1.23
  - Result: reported results
  source text: Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/0001193125-26-218250-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.